Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $30.31 Million Stake in Pfizer Inc. $PFE

Key Points

• Commonwealth of Pennsylvania Public School Employees’ Retirement System reduced its Pfizer stake by 5% in the second quarter, selling 65,593 shares and retaining 1.26 million shares valued at approximately $30.31 million. Institutional investors collectively own 68.36% of Pfizer.
• Pfizer reported quarterly EPS of $0.77 and revenue of $15.03 billion, beating analyst expectations, while revenue increased 2.6% year over year. The company issued fiscal 2026 EPS guidance of $2.80–$3.00.
• Pfizer declared a quarterly dividend of $0.43 per share, implying a 6.4% annualized yield, but its payout ratio remains elevated at 226.32%. Analysts maintain a consensus “Hold” rating with an average price target of $28.28, compared with a recent share price of $26.77.

Commonwealth of Pennsylvania Public School Empls Retrmt SYS reduced its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 5.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,258,852 shares of the biopharmaceutical company's stock after selling 65,593 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS's holdings in Pfizer were worth $30,313,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC lifted its holdings in shares of Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC boosted its position in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after acquiring an additional 2,087 shares during the period. United Bank grew its stake in shares of Pfizer by 12.4% in the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company's stock valued at $1,408,000 after acquiring an additional 6,415 shares in the last quarter. Sei Investments Co. grew its stake in shares of Pfizer by 31.5% in the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company's stock valued at $63,889,000 after acquiring an additional 631,523 shares in the last quarter. Finally, HUB Investment Partners LLC increased its position in Pfizer by 45.3% during the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company's stock worth $2,480,000 after acquiring an additional 31,896 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Down 0.1%

Shares of Pfizer stock opened at $26.77 on Friday. The company has a market capitalization of $152.60 billion, a price-to-earnings ratio of 35.23 and a beta of 0.34. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 12-month low of $23.58 and a 12-month high of $28.75. The firm's 50-day moving average price is $25.12 and its two-hundred day moving average price is $26.20.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same period in the previous year, the company earned $0.78 EPS. The business's revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.4%. The ex-dividend date is Friday, July 24th. Pfizer's payout ratio is currently 226.32%.

Analyst Ratings Changes

PFE has been the subject of several analyst reports. Cantor Fitzgerald reiterated a "neutral" rating and issued a $27.00 price objective on shares of Pfizer in a research note on Monday, July 6th. Bank of America decreased their target price on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a research report on Friday, July 10th. Wolfe Research reaffirmed an "underperform" rating and set a $26.00 target price on shares of Pfizer in a report on Thursday, May 14th. JPMorgan Chase & Co. dropped their price target on shares of Pfizer from $30.00 to $28.00 and set a "neutral" rating for the company in a research report on Wednesday, July 8th. Finally, Wall Street Zen upgraded Pfizer from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of "Hold" and an average price target of $28.28.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla purchased approximately $1 million of Pfizer stock—about 38,000 shares—in his first open-market purchase of the company’s shares. The transaction may reassure investors that management views the current valuation as attractive. Pfizer CEO Buys $1 Million of Company Stock
• Positive Sentiment: The European Medicines Agency validated Pfizer and Valneva’s application for their six-valent Lyme disease vaccine candidate, PF-07307405, beginning the formal review process. The filing is supported by Phase 3 results showing more than 70% efficacy and no significant safety concerns. Validation is an important regulatory milestone, although it does not represent approval. Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
• Positive Sentiment: An updated Korean real-world study of Paxlovid highlighted continued potential value for high-risk COVID-19 patients, supporting Pfizer’s effort to maintain demand for its antiviral as COVID-related revenue normalizes. Pfizer’s Korean Paxlovid Study Signals Ongoing Value in High-Risk COVID Market
• Neutral Sentiment: Erste Group Bank raised its fiscal 2026 EPS forecast, adding modest analyst support. Pfizer’s broader investment case also continues to rely on its non-COVID portfolio, including positive Phase 3 LITFULO data and recently acquired products.
• Negative Sentiment: Investors remain focused on Pfizer’s post-COVID revenue declines, recent intangible-asset impairments, and the discontinuation of its BEQVEZ hemophilia gene therapy, which underscore execution and pipeline risks. Gene Therapy Remains Top-of-Mind in Hemophilia

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source